OBJECTIVES: : Quality of life (QOL) is reportedly poor in children with Crohn disease (CD) but improves with increasing disease duration. This article aims to detail QOL in a cohort of Australian children with CD in relation to disease duration, disease activity, and treatment. MATERIALS AND METHODS: : QOL, assessed using the IMPACT-III questionnaire, and disease activity measures, assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), were available in 41 children with CD. For this cohort, a total of 186 measurements of both parameters were available. RESULTS: : QOL was found to be significantly lower, and disease activity significantly higher (F = 31.1, P = 0.00), in patients within 6 months of their diagnosis compared with those up to 2.5 years, up to 5 years, and beyond 5 years since diagnosis. Higher disease activity was associated with poorer QOL (r = -0.51, P = 0.00). Total QOL was highest in children on nil medications and lowest in children on enteral nutrition. The PCDAI (t = -6.0, P = 0.00) was a significant predictor of QOL, with the clinical history (t = -6.9, P = 0.00) and examination (t = -2.9, P = 0.01) sections of the PCDAI significantly predicting QOL. Disease duration, age, or sex was neither related to nor significant predictors of QOL, but height z score and type of treatment approached significance. CONCLUSIONS: : Children with CD within 6 months of their diagnosis have impaired QOL compared with those diagnosed beyond 6 months. These patients, along with those with growth impairment, ongoing elevated disease activity with abdominal pain, diarrhoea and/or perirectal and extraintestinal complications, may benefit from regular assessments of QOL as part of their clinical treatment.
OBJECTIVES: : Quality of life (QOL) is reportedly poor in children with Crohn disease (CD) but improves with increasing disease duration. This article aims to detail QOL in a cohort of Australian children with CD in relation to disease duration, disease activity, and treatment. MATERIALS AND METHODS: : QOL, assessed using the IMPACT-III questionnaire, and disease activity measures, assessed using the Pediatric Crohn's Disease Activity Index (PCDAI), were available in 41 children with CD. For this cohort, a total of 186 measurements of both parameters were available. RESULTS: : QOL was found to be significantly lower, and disease activity significantly higher (F = 31.1, P = 0.00), in patients within 6 months of their diagnosis compared with those up to 2.5 years, up to 5 years, and beyond 5 years since diagnosis. Higher disease activity was associated with poorer QOL (r = -0.51, P = 0.00). Total QOL was highest in children on nil medications and lowest in children on enteral nutrition. The PCDAI (t = -6.0, P = 0.00) was a significant predictor of QOL, with the clinical history (t = -6.9, P = 0.00) and examination (t = -2.9, P = 0.01) sections of the PCDAI significantly predicting QOL. Disease duration, age, or sex was neither related to nor significant predictors of QOL, but height z score and type of treatment approached significance. CONCLUSIONS: : Children with CD within 6 months of their diagnosis have impaired QOL compared with those diagnosed beyond 6 months. These patients, along with those with growth impairment, ongoing elevated disease activity with abdominal pain, diarrhoea and/or perirectal and extraintestinal complications, may benefit from regular assessments of QOL as part of their clinical treatment.
Authors: Helene Werner; Markus A Landolt; Patrick Buehr; Rebekka Koller; Andreas Nydegger; Johannes Spalinger; Klaas Heyland; Susanne Schibli; Christian P Braegger Journal: Qual Life Res Date: 2017-02-14 Impact factor: 4.147
Authors: Emily R Perito; Tonya M Palermo; John F Pohl; Maria Mascarenhas; Maisam Abu-El-Haija; Bradley Barth; Melena D Bellin; Douglas S Fishman; Steven Freedman; Cheryl Gariepy; Matthew Giefer; Tanja Gonska; Melvin B Heyman; Ryan W Himes; Sohail Z Husain; Tom Lin; Quin Liu; Asim Maqbool; Brian McFerron; Veronique D Morinville; Jaime D Nathan; Chee Y Ooi; Sue Rhee; Sarah Jane Schwarzenberg; Uzma Shah; David M Troendle; Steven Werlin; Michael Wilschanski; Yuhua Zheng; Miriam Bridget Zimmerman; Mark Lowe; Aliye Uc Journal: J Pediatr Gastroenterol Nutr Date: 2020-01 Impact factor: 2.839
Authors: Anu E Castaneda; Annamari Tuulio-Henriksson; Eeva T Aronen; Mauri Marttunen; Kaija-Leena Kolho Journal: World J Gastroenterol Date: 2013-03-14 Impact factor: 5.742
Authors: Luuk Stapersma; Gertrude van den Brink; Jan van der Ende; Alexander G Bodelier; Herbert M van Wering; Pamela C W M Hurkmans; M Luisa Mearin; Andrea E van der Meulen-de Jong; Johanna C Escher; Elisabeth M W J Utens Journal: Int J Behav Med Date: 2019-08
Authors: Luuk Stapersma; Gertrude van den Brink; Jan van der Ende; Eva M Szigethy; Michael Groeneweg; Frederieke H de Bruijne; Manon H J Hillegers; Johanna C Escher; Elisabeth M W J Utens Journal: J Clin Psychol Med Settings Date: 2020-09